Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
PH and SEC7 domain-containing protein 4 (PSD4) is a member of the guanine nucleotide exchange factor (GEF) family that specifically activates small GTPases in the ARF family, notably ARF6 and ARL14/ARF7[1]. The protein contains pleckstrin homology (PH) and Sec7 domains; the PH domain enables phospholipid binding, and the Sec7 domain confers GEF activity. Through activation of ARF6 and ARL14, PSD4 regulates signal transduction related to actin cytoskeleton remodeling and membrane recycling, especially in immune cells such as dendritic cells, by controlling movement of MHC class II vesicles. PSD4 is located primarily at ruffle membranes in cells, consistent with roles in dynamic membrane processes[1][3]. No approved drugs target this molecule, and no direct disease associations are high-confidence, although its molecular function suggests possible involvement in processes critical to immunity and cell trafficking.
Not applicable (no drugs established yet). Putative mechanism for a hypothetical drug would be inhibition or modulation of GEF activity for ARF6/ARF7, affecting signal transduction and membrane trafficking
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on PH and SEC7 domain-containing protein 4 (PSD4).